OssiFi has a management team with deep expertise in discovering, developing, and commercializing novel therapeutics.
Management Team
Clinical Advisors
Pierce Nunley, MD (Louisiana Spine Institute)
Sigurd Berven, MD (UCSF Orthopedics)
John Williams, MD (Orthopedics Northeast)
John Peloza, MD (Midwest Orthopedic & Spine)
Paul Anderson, MD (Emeritus Professor of Orthopedic, UWI)
Frank Rauch, MD (Orthopedic Pediatrics, Shriners & McGill)
Partners
Privately held company. Since its inception, it has been capitalized using convertible notes, non-dilutive grants, and equity.
OssiFi is developing best in class sclerostin small molecule inhibitors to take advantage of new opportunities to develop safer, more effective bone building therapies.
Sign up to keep updated on OssiFi news.
OssiFi takes pride in finding the perfect match for our team. We have created a culture that resonates our innovation.
ABOUT US
OssiFi Therapeutics is an innovative bone-biology company operating at the intersection of therapeutics and medical devices to address significant unmet needs in neurogenic low back pain, fracture repair, and fracture prevention.
